Zhong Jianli

Hainan Institute of Biotechnology, Haikou, 570206, Hainan, China
Author    Correspondence author
International Journal of Clinical Case Reports, 2024, Vol. 14, No. 3   
Received: 30 Apr., 2024    Accepted: 03 Jun., 2024    Published: 13 Jun., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study provides an in-depth analysis of long-term management strategies for patients with hypertensive heart disease (HHD), focusing on classic clinical cases. Hypertensive heart disease is a major contributor to global morbidity and mortality, driven by prolonged high blood pressure, leading to structural and functional changes in the cardiovascular system, such as left ventricular hypertrophy and heart failure. The study reviews the importance of early detection, comprehensive management, and the combination of pharmacological and non-pharmacological interventions. Medications like ACE inhibitors, beta-blockers, and calcium channel blockers are highlighted for their role in controlling blood pressure and reducing cardiovascular complications. Non-pharmacological approaches, including lifestyle modifications, regular monitoring, and patient adherence, are also crucial in managing HHD effectively. Challenges such as patient compliance, the management of comorbidities, and the need for personalized treatment strategies are explored. Emerging therapies and the potential of personalized medicine, especially through genetic and biomarker studies, are discussed as promising avenues for improving outcomes. The study aims to provide clinicians and researchers with valuable insights into improving patient care and the prognosis of those affected by hypertensive heart disease.

Hypertensive heart disease; Long-term management; Pharmacological interventions; Non-pharmacological interventions; Personalized medicine